# Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor

> **NCT00049127** · PHASE1,PHASE2 · COMPLETED · sponsor: **Alliance for Clinical Trials in Oncology** · enrollment: 64 (actual)

## Conditions studied

- Adult Anaplastic Oligodendroglioma
- Adult Mixed Glioma
- Adult Oligodendroglioma
- Recurrent Adult Brain Neoplasm

## Interventions

- **DRUG:** Imatinib Mesylate
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacological Study

## Key facts

- **NCT ID:** NCT00049127
- **Lead sponsor:** Alliance for Clinical Trials in Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-06
- **Primary completion:** 2011-08
- **Final completion:** 2019-09-01
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2019-10-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00049127

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00049127, "Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00049127. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*